Boston Scientific stock edges higher as cyberattack fallout clouds 2026 guidance

Published on 09/14/2026 at 15:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock closed at USD 42.98 on the NYSE on September 11, 2026, after a cyberattack that the company says will likely derail its 2026 guidance. The medical device group now expects a material impact on third-quarter and full-year results while operations have been fully restored.

Sterile Fertigungslinie für Herzkathetersysteme in einem Medizintechnik-Reinraum in Marlborough MA — Boston Scientific Corp. betreibt sterile Reinraumfertigung für Herzkathetersysteme am Standort Marlborough MA, ISIN US10117L1017, Illustration mit AI erstellt.

Boston Scientific stock closed at USD 42.98 on the NYSE on September 11, 2026, down 0.28% from the prior session, before pre-market trading on September 14, 2026 pointed to a modest rebound in the wake of a significant cyberattack disclosure.

Cyberattack forces guidance rethink

According to Yahoo Finance on September 13, 2026, Boston Scientific Corporation reported that an August 25, 2026 cyberattack disrupted manufacturing and shipping and is expected to have a material impact on its third-quarter and full-year 2026 net sales and adjusted earnings per share guidance.

The company stated that, based on currently available information, it is unlikely to meet its previously issued guidance for net sales growth and adjusted EPS in 2026, which had been communicated in late July 2026, and that the cyber incident will weigh on results despite operations having resumed.

As Security Measures Lab reported on September 14, 2026, Boston Scientific detailed in a Form 8-K filed with the SEC on September 8, 2026 that the incident is likely to significantly affect its results for the third quarter and full year 2026, prompting the company to warn that its previously communicated guidance for 2026 sales growth and adjusted EPS may not be achieved.

Operations restored but risks remain

Despite the guidance downgrade, Boston Scientific emphasized that core operations have returned to normal, with manufacturing, order processing and product shipments fully restored by September 9, 2026, roughly two weeks after the August 25, 2026 incident, according to Security Measures Lab.

The same report notes that Boston Scientific and external cybersecurity experts such as CrowdStrike found no evidence of compromise in product technology or several key systems, and the company currently does not expect the cyberattack to have a major long-term impact on its financial position, even though the short-term hit to 2026 earnings is assessed as significant.

The attack also led to a temporary halt and subsequent resumption of remote monitoring enablement for cardiac device communicators and insertable cardiac monitors, a sensitive area for patients and physicians that Boston Scientific addressed once the technical problem was resolved, as outlined by Security Measures Lab.

Recent price performance and market context

Per NYSE quote data compiled by a major stock portal, Boston Scientific stock finished the September 11, 2026 session at USD 42.98, down 0.12 dollars or 0.28% on the day, with after-hours indications lifting the price above USD 43.00 and pre-market data on September 14, 2026 pointing to a level of around USD 43.41, up roughly 1.00% versus the prior close.

The same overview shows that the shares are trading close to consensus analyst fair value, with the current price of USD 42.98 compared against an average analyst price target around USD 62.41, implying substantial upside based on that metric, and a recent single-house target of USD 56.00 that was cut from USD 60.00 as of September 9, 2026.

This adjustment came from BTIG, which maintained a Buy rating while lowering its price target from USD 60.00 to USD 56.00 on September 9, 2026, according to Yahoo Finance, indicating that at least some analysts see the cyberattack and guidance uncertainty as reasons to trim expectations even as they stay positive on the stock longer term.

Fundamentals and guidance backdrop

Boston Scientific entered the cyberattack period on the back of recent growth, having previously guided for 2026 net sales expansion and adjusted EPS improvement compared with 2025, though detailed figures for that guidance come from company communications in late July 2026 and are now flagged as at risk in the September 8, 2026 Form 8-K mentioned by Security Measures Lab.

While specific quarterly revenue and earnings numbers for 2026 are not highlighted in the week-filtered sources, the company’s statement that the cyber incident will materially affect both third-quarter and full-year 2026 performance gives investors a clear line of comparison: previously indicated growth is now expected to be meaningfully lower than initially planned, and adjusted EPS for 2026 is likely to miss the range presented in July 2026.

For context on operational risk, a medical device news digest reported that on September 3, 2026 the US Food and Drug Administration posted a serious recall of unused Boston Scientific Infinion CX leads used with spinal cord stimulation systems, identifying mechanical stress at the lead anchor site as a source of high impedance or fractures, with 1,081 serious injuries reported as of May 27, 2026 and no deaths, according to Simone Ronco.

Analyst stance and investor takeaway

Analyst sentiment toward Boston Scientific remains broadly constructive despite near-term headwinds, as evidenced by BTIG’s decision to maintain a Buy rating with a reduced USD 56.00 target in its September 9, 2026 action, even though that new target sits USD 4.00 below the prior USD 60.00 level, a cut of about 6.7%, according to the price-target section of Yahoo Finance.

For retail investors, the key comparison is between the current trading level around USD 43.00 and the wider analyst consensus, which stands markedly higher, implying that the market has partially priced in the cyberattack and recall risks but still sees room for recovery if Boston Scientific can stabilize execution and demonstrate that the 2026 earnings drag remains confined to the short term.

At the same time, the recall involving Infinion CX leads and the cyberattack together underline the operational and regulatory risks inherent in the medical device sector, suggesting that Boston Scientific’s valuation will remain sensitive to further updates on product safety, cyber resilience and the pace at which revenue and margins normalize in 2026 and beyond.

Stock level on the NYSE

Boston Scientific stock, listed on the NYSE under the ticker BSX, last closed at USD 42.98 on September 11, 2026, with pre-market indications on September 14, 2026 showing trading around USD 43.41 in USD, leaving the shares below typical analyst targets but supported by the company’s message that the cyberattack should not have a major long-term impact on its financial position.